Technology | Ablation Systems | February 16, 2017

FDA Approves Expanded Indication for Medtronic Freezor Xtra Cryoablation Catheter

Device demonstrated safe and effective for treating patients with abnormal heart rhythm of AVNRT

Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia

February 16, 2017 — Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter for treating patients with atrioventricular nodal re-entrant tachycardia (AVNRT), a life- threatening abnormal heart rhythm.

The Freezor Xtra Catheter is a flexible, single-use device used to freeze cardiac tissue and block unnecessary electrical signals within the heart.

AVNRT is an abnormal heart rhythm, or arrhythmia; approximately 319,000 people live with AVNRT and more than 49,000 people are diagnosed each year.1, 2

“The expanded indication for this catheter will allow more patients to benefit from a safe and effective therapy that can prevent heart racing, and allow them to get back to their normal activities,” said Peter Wells, M.D., heart rhythm doctor at Baylor Heart and Vascular Hospital, Dallas, and principal investigator of the Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia (ICY-AVNRT) clinical trial.

The expanded indication is supported by data from ICY-AVNRT clinical study, which demonstrated safety and effectiveness of the Freezor Xtra Catheter for the treatment of patients with AVNRT. With 397 enrolled patients in 34 clinical trial sites across the United States and Canada, the study showed freedom from AVNRT was 92.6 percent at six months post-procedure. All of the safety endpoints were met, with no primary safety events related to the Freezor Xtra Catheter.

For more information: www.medtronic.com

Related Content

Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM)| March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM)| March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies| March 14, 2017
More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no...
Micra leadless pacemaker, CMS, medicare reimbursement
News | Pacemakers| March 10, 2017
March, 10, 2017 - Medtronic announced that the U.S.
Zoll, Hospital Wearable Defibrillator, HWD, FDA premarket approval
Technology | Defibrillator Monitors| March 10, 2017
Zoll Medical Corp. announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket...
Medtronic, CRT-D, REVERSE Trial analysis, cost-effectiveness, Michael R. Gold, JACC Heart Failure
News | Cardiac Resynchronization Therapy Devices (CRT)| March 07, 2017
March 7, 2017 — Medtronic plc recently announced an economic analysis of five-year data showing that patients with mi
Overlay Init